Business Description
SanBio is a Tokyo-based biopharmaceutical company founded in 2001 that creates cell-based therapies to treat diseases and injuries of the brain and nervous system. Its lead product, SB623, has already completed a Phase 2 clinical trial for traumatic brain injury in both the United States and Japan. The company is also working on a broad range of additional treatments targeting conditions such as Parkinson's disease, Alzheimer's disease, spinal cord injury, cancer, and muscular dystrophy, among others.
